Trending...
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
- 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
- Tickeron Launches Next-Gen AI Corridor Bots: Consistent Exits for Stocks and ETFs
TORONTO and PHILADELPHIA, Sept. 21, 2023 ~ MolecuLight Inc., a leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, presented 6 Clinical Posters, a Presentation, and a Hands-On Workshop at the American Professional Wound Care Association's (APWCA) Wound Week™. The event was held from September 20 - 24, 2023 in Philadelphia, PA.
Dr. Thomas Serena, the Founder and Medical Director of The SerenaGroup®, commented on the importance of MolecuLight's point-of-care imaging of bacterial load as an essential tool for all wound care practitioners. He said that the evidence is irrefutable and that it is supported by the results of their 1,447 patient, multi-center study titled "Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging". The use of MolecuLight reduced antibiotic usage by 78%, showing that identifying and characterizing elevated bacterial loads in wounds can help clinicians make more informed decisions and provide the most appropriate treatment.
More on The PennZone
Anil Amlani, MolecuLight's CEO expressed his excitement about the significant additional clinical evidence being presented at Wound Week 2023 showing the impressive results derived from MolecuLight point-of-care devices. He said that these clinical insights span the wound care continuum including wound hygiene, wound bed preparation, antimicrobial stewardship, and patient engagement (through the incorporation of MolecuLight). In addition to these benefits, MolecuLight is helping combat racial inequity by being an imaging technology that elevates the detection of bacteria across all skin tones. Involving MolecuLight in patient care has improved wound healing outcomes as shown by results from a new 12-week randomized controlled trial.
The 6 clinical posters and presentation featuring the MolecuLight i:X at Wound Week 2023 were presented by Dr. Alisha Oropallo (Northwell Comprehensive Wound Healing Center), Dr. Charles Andersen (Vascular/Endovascular/Limb Preservation Surgery Service), and Dr. Thomas Serena (SerenaGroup Research Foundation). These posters included 12-week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates; Pseudomonas Scrub Down: Advances in Wound Imaging Objectively Confirm the Efficacy of Acetic Acid Against this Pathogen; Bacterial load imaging of chronic wound bacteria supports patient adherence, empowerment and may prevent negative outcomes; Strategies to improve equity in wound bacterial-infection assessments on skin of color; Multimodal imaging device for real-time bacterial load and thermal imaging: a study of synergy in clinical wound assessment workflow; Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging; Co-localization of High Bacterial Load with Regions of Pain in Venous Leg Ulcers: Imaging Informs Interventions and Validates Patient Self-Reported Pain.
More on The PennZone
The Hands-On Skills Workshop was held on Saturday September 23rd from 2:45 pm – 4:45 pm where attendees had an opportunity to experience first hand how to use MolecuLight i:X® and DX™ imaging devices for themselves. They were also available for demonstration at booth #40 located in Exhibit Hall throughout Wound Week 2023.
MolecuLight Inc.'s presence at APWCA's Wound Week™ provided attendees with valuable insights into how their point-of-care fluorescence imaging can be used to detect elevated bacterial loads within wounds which can help clinicians make more informed decisions when providing treatment options to their patients while also helping combat racial inequity through its ability to detect bacteria across all skin tones.
Dr. Thomas Serena, the Founder and Medical Director of The SerenaGroup®, commented on the importance of MolecuLight's point-of-care imaging of bacterial load as an essential tool for all wound care practitioners. He said that the evidence is irrefutable and that it is supported by the results of their 1,447 patient, multi-center study titled "Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging". The use of MolecuLight reduced antibiotic usage by 78%, showing that identifying and characterizing elevated bacterial loads in wounds can help clinicians make more informed decisions and provide the most appropriate treatment.
More on The PennZone
- Holiday Decorations Most Likely to Cause Injuries
- UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
- Zac Arbitman Elected As Co-Chair of Philadelphia Bar Association Federal Courts Committee
- CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
- BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
Anil Amlani, MolecuLight's CEO expressed his excitement about the significant additional clinical evidence being presented at Wound Week 2023 showing the impressive results derived from MolecuLight point-of-care devices. He said that these clinical insights span the wound care continuum including wound hygiene, wound bed preparation, antimicrobial stewardship, and patient engagement (through the incorporation of MolecuLight). In addition to these benefits, MolecuLight is helping combat racial inequity by being an imaging technology that elevates the detection of bacteria across all skin tones. Involving MolecuLight in patient care has improved wound healing outcomes as shown by results from a new 12-week randomized controlled trial.
The 6 clinical posters and presentation featuring the MolecuLight i:X at Wound Week 2023 were presented by Dr. Alisha Oropallo (Northwell Comprehensive Wound Healing Center), Dr. Charles Andersen (Vascular/Endovascular/Limb Preservation Surgery Service), and Dr. Thomas Serena (SerenaGroup Research Foundation). These posters included 12-week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates; Pseudomonas Scrub Down: Advances in Wound Imaging Objectively Confirm the Efficacy of Acetic Acid Against this Pathogen; Bacterial load imaging of chronic wound bacteria supports patient adherence, empowerment and may prevent negative outcomes; Strategies to improve equity in wound bacterial-infection assessments on skin of color; Multimodal imaging device for real-time bacterial load and thermal imaging: a study of synergy in clinical wound assessment workflow; Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging; Co-localization of High Bacterial Load with Regions of Pain in Venous Leg Ulcers: Imaging Informs Interventions and Validates Patient Self-Reported Pain.
More on The PennZone
- UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
- Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
- Twin Flame Visions Announces Surge in Traffic and Engagement Following Breakout Ad Performance
- FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
- Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California
The Hands-On Skills Workshop was held on Saturday September 23rd from 2:45 pm – 4:45 pm where attendees had an opportunity to experience first hand how to use MolecuLight i:X® and DX™ imaging devices for themselves. They were also available for demonstration at booth #40 located in Exhibit Hall throughout Wound Week 2023.
MolecuLight Inc.'s presence at APWCA's Wound Week™ provided attendees with valuable insights into how their point-of-care fluorescence imaging can be used to detect elevated bacterial loads within wounds which can help clinicians make more informed decisions when providing treatment options to their patients while also helping combat racial inequity through its ability to detect bacteria across all skin tones.
Filed Under: Business
0 Comments
Latest on The PennZone
- Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody
- Compliance Is the Ticket to Entry: Legal Advisor Gabriela Moraes Analyzes RWA Securitization Paths Under Brazil's New Legislation
- Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban
- Spark Announces 2025 Design Award Winners
- NEW Luxury Single-Family Homes Coming Soon to Manalapan - Pre-Qualify Today for Priority Appointments
- Together We Dance Shines at Newtown Holiday Parade
- Dominic Pace Returns to the NCIS Franchise With Guest Role on NCIS: Origins
- Anderson Periodontal Wellness Attends 5th Joint Congress for Ceramic Implantology
- UK Financial Ltd Completes Full Ecosystem Conversion With Three New ERC-3643 SEC-Ready Tokens As MCAT Deadline Closes Tonight
- AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
- Inkdnylon Expands National Uniform Embroidery Services
- Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
- Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
- Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
- Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
- Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
- Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
- KIKO NATION TOKEN (Official Release)
- Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology
- Psoriasis Drugs Market Poised to Hit 20 Billion Dollars in 2025 says SNS Research in Latest Report